# ResMed Inc. (RMD)

> Source: Nexqual · https://nexqual.com/RMD · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, ResMed Inc. (RMD), nexqual.com/RMD" · informational, not investment advice.

**Price:** USD 252.83 (+1.06% on the day) · last close of Oct 29, 2026; US market after hours, not a live price. Prev close 250.17 · day 249.6–254.27 · 52w 180.27–277.67 · market cap $35.6B · NYQ

## Key facts
- Analysts: Hold (mean 2.50 on a 1–5 scale) (20 analysts), mean target USD 251.52 (range 175–320).
- Next earnings: 2026-10-29, EPS estimate USD 2.67, revenue estimate $1.39B.

## Analysts
Consensus Hold (mean 2.50 on a 1–5 scale), 20 analysts; mean target USD 251.52 (low 175, high 320).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | RBC Capital | Upgrade | Sector Perform → Outperform | $244 → $262 |
| 2026-08-31 | Keybanc | Target raised | Overweight | $255 → $267 |
| 2026-08-19 | Rothschild & Co | Initiated | Neutral | $230 |
| 2026-08-07 | RBC Capital | Target raised | Sector Perform | $234 → $244 |
| 2026-08-07 | Piper Sandler | Target lowered | Neutral | $233 → $225 |
| 2026-08-07 | Keybanc | Target lowered | Overweight | $260 → $255 |
| 2026-08-07 | Wells Fargo | Target lowered | Equal-Weight | $225 → $215 |
| 2026-07-15 | Mizuho | Target lowered | Outperform | $235 → $220 |
| 2026-07-13 | Citigroup | Downgrade | Buy → Neutral | $270 → $235 |
| 2026-07-10 | Jefferies | Target lowered | Hold | $240 → $225 |
| 2026-07-08 | RBC Capital | Target lowered | Outperform | $321 → $276 |
| 2026-07-08 | Wells Fargo | Target lowered | Equal-Weight | $227 → $225 |

## More
Full page: https://nexqual.com/RMD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.67 | $2.83 | -5.5% | $1.39B | 13 |
| Next quarter (ends 2026-12-31) | $3.02 | $3.01 | +0.3% | $1.45B | 13 |
| Current fiscal year (ends 2027-06-30) | $12.09 | $11.95 | +1.2% | $5.80B | 20 |
| Next fiscal year (ends 2028-06-30) | $13.26 | $13.03 | +1.7% | $6.18B | 20 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $2.95 | $2.89 | Beat +2.1% | — |
| — | Quarter ended Mar 31, 2026 | $2.86 | $2.80 | Beat +2.1% | — |
| — | Quarter ended Dec 31, 2025 | $2.81 | $2.72 | Beat +3.3% | — |
| — | Quarter ended Sep 30, 2025 | $2.55 | $2.50 | Beat +2.0% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-29 | 8-K | Quarterly results; Other material event — “On October 29, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed's common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ("CDIs") trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record…” | https://www.sec.gov/Archives/edgar/data/943819/000119312526437783/0001193125-26-437783-index.htm |
| 2026-10-01 | DEFA14A | Additional proxy material | https://www.sec.gov/Archives/edgar/data/943819/000094381926000082/0000943819-26-000082-index.htm |
| 2026-10-01 | DEF 14A | Proxy statement (pay, board, votes) · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/943819/000094381926000080/0000943819-26-000080-index.htm |
| 2026-09-01 | 8-K | Other material event — “On August 31, 2026, ResMed Inc. (the "Company") entered into an accelerated share repurchase agreement (the "ASR Agreement") with Citibank, N.A. ("Citibank") to repurchase $450.0 million of the Company's shares of common stock, par value $0.004 per share ("Common Stock"). The Company is conducting the accelerated share repurchase under a repurchase authorization for an aggregate of 20,000,000 shares of Common Stock approved by its board of directors in February 2014. The Company intends to fund the accelerated…” | https://www.sec.gov/Archives/edgar/data/943819/000119312526378487/0001193125-26-378487-index.htm |
| 2026-08-17 | 8-K | Auditor changed; Director or executive officer change, or pay arrangement; Regulation FD disclosure — “(a) Dismissal of Previous Independent Registered Public Accounting Firm KPMG LLP ("KPMG") was previously the principal accountants for ResMed Inc. (the "Company" or "Resmed"). On August 13, 2026, KPMG was dismissed, effective as of that date. The reports of KPMG on the Company's consolidated financial statements for the fiscal years ended June 30, 2026 and 2025 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles.…” | https://www.sec.gov/Archives/edgar/data/943819/000119312526354154/0001193125-26-354154-index.htm |
| 2026-08-13 | 10-K | Annual report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/943819/000094381926000047/0000943819-26-000047-index.htm |
| 2026-08-07 | Schedule 13G | AustralianSuper Pty Ltd: 5.7% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/943819/000169416426000006/0001694164-26-000006-index.htm |
| 2026-08-06 | 8-K | Quarterly results; Other material event — “On August 6, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share, representing an increase of 10% over the previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed's common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests ("CDIs") trading on the Australian Securities Exchange will receive an equivalent…” | https://www.sec.gov/Archives/edgar/data/943819/000119312526337962/0001193125-26-337962-index.htm |
| 2026-07-07 | 8-K | Quarterly results; Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/0001193125-26-297658-index.htm |
| 2026-07-01 | Schedule 13G/A | Reported a 1.9% stake in Nyxoah SA | https://www.sec.gov/Archives/edgar/data/943819/000119312526291475/0001193125-26-291475-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.